AUTHORS
Uday Popat, MD, MBA, Rima M. Saliba, PhD2, Amin Alousi, MD3, Gheath Alatrash, PhD4, Yosra M. Aljawai, MD MS5, Qaiser Bashir, MD6, George Chen, MD7, Warren Fingrut, MD, MPH8, Chitra Hosing, MD9, Jin Im, MD, PhD10, Partow Kebriaei, MD11, David Marin12, Rohtesh Mehta, MD, MPH13, Yago Nieto, MD, Ph.D14, Amanda Olson, MD15, Betul Oran, MD16, Jeremy Ramdial, MD17, Gabriela Rondon, MD18, Neeraj Saini, MD19, Terri Lynn Shigle20, Portia Smallbone, MBBS (Hons), FRACP, FRCPA21, Samer A Srour, MB ChB, MS22, Muzaffar Qazilbash, MD23, Naval Daver, MD24, Tapan Kadia I, MD25, Courtney DiNardo, MD, MSCE26, Issa F. Khouri, MD27, Guillermo Garcia-Manero, MD28, Richard Champlin29, Elizabeth Shpall, MD30
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Outcomes after allogeneic stem cell transplantation (alloHCT) remain poor for older patients with high-risk acute myeloid leukemia (AML), with fewer than half achieving long-term survival despite transplantation. Treatment failure results from both high non-relapse mortality (NRM), driven by conditioning toxicity and graft-versus-host disease (GVHD), and persistent disease relapse.
To reduce regimen-related toxicity while maintaining myeloablative intensity, we previously developed a fractionated busulfan platform that extends busulfan administration over three weeks. GVHD was minimized using post-transplant cyclophosphamide (PTCy), while cladribine, thiotepa, and venetoclax—agents with established activity against AML—were incorporated to enhance anti-leukemic efficacy. We previously demonstrated encouraging outcomes with this intensified regimen in younger patients (Popat et al., ASH 2025). Here, we report the safety and efficacy of a modified reduced-toxicity version (Cladillac-R) designed for older and medically infirm patients.
Methods
Busulfan exposure was reduced for older and medically infirm patients while preserving a myeloablative conditioning backbone. Patients received outpatient busulfan 80 mg/m² on days −20 and −13, followed by thiotepa 5mg/kg on day -7 and ludarabine 10 mg/m², cladribine 10 mg/m², and pharmacokinetically targeted busulfan on days −6 through −3 to achieve a cumulative exposure of 16,000 ± 12% μmol·min/L. Venetoclax 400 mg daily was administered from days −22 through −3. GVHD prophylaxis consisted of PTCy (50 mg/kg on days +3 and +4), tacrolimus, and mycophenolate mofetil.
Results
Between February 2023 and April 2025, 60 consecutive patients with AML in complete remission who were considered unsuitable for conventional myeloablative conditioning because of age and/or comorbidities underwent alloHCT using Cladillac-R.
The median age was 66 years (range, 21–76; IQR, 57–70); 43% were female. Disease characteristics reflected a high-risk population: 87% were in CR1, 13% in CRi, 55% were MRD-positive before transplant, 58% had ELN 2022 adverse-risk disease, 23% had secondary or therapy-related AML, and 10% harbored TP53 mutations. Patients received a median of one prior induction regimen (range, 1–3), and the median interval from AML diagnosis to transplant was 4.8 months. Donors included matched unrelated (57%), matched sibling (18%), haploidentical (12%), and mismatched unrelated (13%). The median HCT-CI score was 2 (range, 0–7), with 43% of patients having an HCT-CI ≥3.
After a median follow-up of 18 months (IQR, 12–31), median overall survival (OS) and progression-free survival (PFS) had not been reached. One-year OS and PFS were 78% (95% CI, 66–87%) and 75% (95% CI, 62–84%), respectively. One-year NRM was 12% (95% CI, 7–25%), while cumulative relapse incidence was only 13% (95% CI, 7–25%).
On multivariable analysis, TP53 mutation (HR 6.6) and HCT-CI ≥3 (HR 3.9) were independently associated with inferior survival. Patients with TP53 wild-type AML achieved a one-year OS of 83% and PFS of 80%.
Median neutrophil and platelet engraftment occurred at 16 (range, 13–24) and 21 (range, 10–40) days, respectively. No graft failures occurred. By day +30, both myeloid and T-cell donor chimerism reached 100%. Grade II–IV acute GVHD occurred in 20% of patients, grade III–IV acute GVHD in 6%, and chronic GVHD in 12%.
Conclusions
Cladillac-R provides a promising reduced-toxicity myeloablative conditioning platform for older and medically infirm patients with high-risk AML, achieving encouraging survival with low non-relapse mortality and relapse. These findings justify prospective evaluation against standard reduced-intensity conditioning regimens.
DISCLOSURES
Uday Popat, MD, MBA: Incyte - Research Funding; Abbvie - Research Funding; Novartis - Research Funding; TScan - Research Funding; Bayer - Research Funding; Daiichi Sankyo - Consultancy (Includes expert testimony); Illuminate Health - Consultancy (Includes expert testimony)